Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
about
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
P2860
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@en
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@nl
type
label
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@en
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@nl
prefLabel
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@en
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@nl
P2093
P2860
P356
P1476
Determinants of the increase i ...... in NGT, IFG and T2DM patients.
@en
P2093
Curtis Triplitt
Eugenio Cersosimo
Hussein Al Jobori
John Adams
Muhammad Abdul-Ghani
P2860
P304
P356
10.1111/DOM.12881
P577
2017-01-27T00:00:00Z